An elevated plasma fibrinogen is a well recognised feature of active rheumatoid arthritis (RA), and the presence of large amounts of fibrin in the synovial fluid and membrane is also well documented in this disease.2 Normally the fate of fibrin, once it is formed, is related to its enzymatic degradation, which is mediated by plasmin. Plasmin is produced, when required, by cleavage of its inactive precursor protein plasminogen. The rate of this reaction is determined by the relative proportions of activators and inhibitors of fibrinolysis present. Plasminogen activator (PA) transforms plasminogen to plasmin and is therefore an activator of fibrinolysis, whereas a2 macroglobulin (a2M) is an inhibitor of fibrinolysis.
Inflammation of the vascular endothelium, as may occur in RA, with subsequent endothelial damage might be expected to decrease the ability of the endothelium to produce PA. It has also been suggested that excessive fibrin deposition may be implicated in the loss of joint mobility and deformity seen in RA,3 and that an excess of deposition over removal may underlie some forms of chronic inflammation.4
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Jasani suggests that intra-articular fibrin deposition may lead to the development of some of the joint manifestations of RA, including pannus formation and polymorph induced cartilage destruction. 4 The fibrinolytic potential of RA patients has therefore been investigated by a number of workers. Unfortunately such studies have produced conflicting results. Feamley et al.5 and others3 suggested a decrease in whole blood fibrinolysis in RA, whereas other workers have found evidence to suggest an increased or normal fibrinolytic potential.
In an effort to clarify the situation the blood fibrinolytic status of 56 patients with RA of varying disease activity has been assessed and compared with that of normal population. RA patients with low fibrinolytic activity were then given stanozolol, a fibrinolytic enhancing agent which increases plasminogen and plasminogen activator levels.7 This drug can be used as a test of endothelial PA production and it can be determined whether it is possible to stimulate fibrinolysis in this disease.
Patients and methods
Fifty-six patients with classical or definite RA, as defined by American Rheumatism Association 774 (Table 1) . In addition to Hb and ESR measurements blood was also drawn for estimation of plasma fibrinogen and fibrinolysis. For these tests blood was anticoagulated with 3-8% trisodium citrate (9:1 v/v). Plasma fibrinogen,9 plasminogen activity,"0 and plasminogen activator activity11 assays were carried out in the standard fashion.
We also measured a2M (radioimmunodiffusion)"2 and PA activity during stanozolol treatment showed a significant increase (paired t test). Similarly plasminogen levels increased in synovial fluid (Table 4) .
Discussion
From our results it can be seen that plasma levels of fibrinogen and plasminogen are significantly raised in patients with RA. Moreover, the levels of fibrinogen, plasminogen, and the inhibitors of fibrinolysis, a2M, and AT III correlate with the degree of disease activity, being highest in those with severe disease. It is well recognised that fibrinogen is an acute phase protein and therefore an elevated level would be expected in active disease. There is also some evidence to suggest that a2M13 and AT 11114 are likewise acute phase proteins, and our work would seem to support this. However, the difference in PA activity seen in the patients with severe RA is not explicable on the basis of an acute phase reaction. Indeed, although the activity of PA is increased in moderate disease, it appears to be depressed in severe disease. This finding would-suggest that either inadequate amounts of PA are being produced or that an inhibitor of PA is present. Experimental work supports the latter.3 Kwaan and Astrup15 suggest that the presence of inhibitors in fibrin clots results in delayed fibrin dissolution and enhanced formation of connective tissue. Fibrin is not normally found in joints,4 presumably because of continual fibrinolysis within the joint by blood vessel production of PA. It could be argued on the basis of these plasma results that this unusual build-up of fibrin in RA joints might be due to inadequate joint fibrinolysis. There is a correlation between levels of blood and synovial fluid protein,3 and indeed fibrinolytic activity in blood and tissue may be related, since in tissues fibrinolysis is most marked round blood vessels. 8 who used the same agent in vasculitis, also detected clinical improvement in the three patients with RA. We gave 12 patients with RA stanozolol, an anabolic steroid with fibrinolytic enhancing effects, to determine whether it was possible to stimulate fibrinolytic activity in this disease. A significant increase in blood PA activity was produced. In order to establish whether stanzolol could enhance fibrinolysis in the active site of the disease, that is, the joints, five patients received stanozolol with aspiration of knee joint effusion before and after. Results confirmed an increase in potential for joint fibrinolysis.
In conclusion we would suggest that inadequate fibrinolysis occurs in RA as measured by PA activity, and that this may contribute to the excess fibrin de- position in the joints, leading to some of the features of RA. In addition we have shown that the fibrinolytic enhancing agent stanozolol can increase plasma and joint fibrinolysis.
Theoretically it should therefore be possible to alleviate some of the symptoms of RA with these agents. A double-blind study to evaluate this hypothesis is under way.
